Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients

Lignende værker

• A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations
  af: Demuth, Christina, et al.
  Udgivet: (2018)
• Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients
  af: Anne Tranberg Madsen, et al.
  Udgivet: (2020-04-01)
• Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients
  af: Madsen, Anne Tranberg, et al.
  Udgivet: (2020)
• Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()
  af: Winther-Larsen, Anne, et al.
  Udgivet: (2016)
• The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
  af: Demuth, Christina, et al.
  Udgivet: (2018)